Group 1 - Tsinghua Dongbao's stock price increased by 5.17% to 9.15 CNY per share, with a trading volume of 269 million CNY and a turnover rate of 1.53%, resulting in a total market capitalization of 17.921 billion CNY [1] - Tsinghua Dongbao Pharmaceutical Co., Ltd. was established on December 28, 1992, and went public on August 24, 1994. The company specializes in hard capsule preparations, tablets (including hormone types), granules, small-volume injections, raw materials (recombinant human insulin), and biopharmaceutical products (recombinant human insulin injection) [1] - The main business revenue composition includes: biopharmaceuticals (raw materials and formulations) at 90.29%, medical devices such as injection pens and blood glucose test strips at 6.07%, traditional Chinese medicine and chemical drugs at 2.24%, and others at 1.27% [1] Group 2 - Among Tsinghua Dongbao's top ten circulating shareholders, a fund under Southern Fund holds a significant position. The Southern CSI 500 ETF (510500) reduced its holdings by 352,900 shares in the third quarter, now holding 17.0539 million shares, which accounts for 0.87% of circulating shares [2] - The Southern CSI 500 ETF (510500) was established on February 6, 2013, with a latest scale of 144.69 billion CNY. Year-to-date returns are 11.19%, ranking 482 out of 5566 in its category, while the one-year return is 51.04%, ranking 1152 out of 4285 [2]

Core Viewpoint - The diabetes medication market in China is experiencing rapid growth due to the increasing prevalence of diabetes driven by an aging population and rising obesity rates, alongside improvements in healthcare infrastructure and public awareness [1][8]. Industry Overview - Diabetes is characterized by chronic hyperglycemia due to insulin secretion and/or utilization defects, classified into Type 1, Type 2, gestational diabetes, and other specific types [2]. - Diabetes medications are categorized into eight classes, including insulin secretagogues, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, SGLT-2 inhibitors, insulin, and GLP-1 receptor agonists [2]. Market Growth - The market size for diabetes medications in China is projected to grow from 47 billion yuan in 2016 to 80.2 billion yuan in 2024, with a compound annual growth rate (CAGR) of 6.91% [1][8]. - By 2025, the market size is expected to reach approximately 85.7 billion yuan [1]. Patient Demographics - The number of diabetes patients in China is expected to increase from 118 million in 2016 to 148 million by 2024, with a CAGR of 2.87% [6][8]. - The adult diabetes prevalence rate in China is currently at 13.79%, which is significantly higher than the global average [6]. Competitive Landscape - The diabetes medication industry in China features a tiered competitive structure, with multinational companies like Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca leading the first tier due to their innovative drug development capabilities [8]. - Domestic companies such as Tonghua Dongbao, Gan & Lee Pharmaceuticals, and Huadong Medicine are emerging as strong competitors in the second tier, particularly in insulin and oral hypoglycemic agents [8]. Industry Trends - Future research and development in diabetes medications will focus on precision and individualized treatment, targeting specific mechanisms of Type 2 diabetes [12]. - The industry is expected to prioritize long-acting, multi-target drugs that modify disease progression, moving beyond mere blood sugar control [13]. - Companies will shift from being mere drug providers to comprehensive health management partners for diabetes patients, utilizing digital health technologies for continuous monitoring and personalized care [14].

● 本报记者 万宇 *ST松发预计2025年实现净利润24亿元-27亿元，扭亏为盈。2025年四季度，多家基金公司旗下产品增持 *ST松发或新进机构投资者名单。其中，谢书英管理的兴全合瑞在2025年四季度增持*ST松发，华夏基 金、工银瑞信基金等公司旗下产品新进该股机构投资者名单。不过，也有基金公司减持*ST松发，如博 时基金旗下产品在2025年四季度合计减持该股738.71万股。 通化东宝预计2025年实现净利润12.42亿元，也实现扭亏为盈。2025年四季度，7家基金公司旗下产品新 进通化东宝机构投资者名单。 宏和科技预计2025年实现净利润1.93亿元-2.26亿元，同比增长745%-889%。2025年四季度，6家基金公 司旗下产品新进宏和科技机构投资者名单。 佰维存储预计2025年实现净利润8.5亿元-10亿元，同比增长427.19%-520.22%。截至2025年底，共有40 家基金公司旗下产品持有佰维存储，多只产品在2025年四季度增持佰维存储。其中，兴证全球基金、永 赢基金、华商基金旗下产品当季增持佰维存储均超100万股，广发基金、汇添富基金旗下产品在2025年 四季度新进佰维存储的机构投资者 ...

Core Insights - Over 2900 A-share listed companies have released their 2025 earnings forecasts, with high-performing companies attracting significant interest from fund institutions [1][2] - Notable companies with substantial profit growth include Zijin Mining, which is expected to achieve a net profit of 510-520 billion yuan, and Industrial Fulian, projected to reach 351-357 billion yuan [2][3] Company Performance - Zijin Mining is expected to see a net profit increase of 59%-62% in 2025, with 78 fund companies holding its shares, including well-known fund managers [2] - Industrial Fulian anticipates a net profit growth of 51%-54%, with 96 fund companies holding its shares, primarily managed by E Fund [3] - *ST Songfa is projected to turn a profit with a net profit of 24-27 billion yuan, attracting new institutional investors in Q4 2025 [4] - Tonghua Dongbao expects a net profit of 12.42 billion yuan, also turning a profit, with new institutional investors entering in Q4 2025 [4] - Honghe Technology forecasts a net profit of 1.93-2.26 billion yuan, showing a significant growth of 745%-889%, with new institutional investors in Q4 2025 [4] - Baiwei Storage anticipates a net profit of 8.5-10 billion yuan, with 40 fund companies holding its shares and several increasing their positions in Q4 2025 [5] Market Outlook - The release of earnings forecasts and annual reports is expected to lead to a focus on companies' performance, with a potential for market stabilization and upward movement [6] - Fund institutions suggest that the market may return to a structure driven by "profit certainty + industry trends," with opportunities in core technology and manufacturing sectors [6] - External factors may create short-term pressure, but domestic policy support and a stable capital market are expected to mitigate significant downturns [7] - Investment strategies are recommended to focus on growth sectors like AI and semiconductors, as well as areas benefiting from "anti-involution" policies, such as new energy [7]

Core Insights - Over 2900 A-share listed companies have released their 2025 earnings forecasts, with several high-performing companies attracting significant interest from fund institutions [1][2] Group 1: High-Performing Companies - Zijin Mining is expected to achieve a net profit of 510 billion to 520 billion yuan in 2025, representing a year-on-year growth of 59% to 62% [2] - Industrial Fulian is projected to realize a net profit of 351 billion to 357 billion yuan in 2025, with a year-on-year increase of 51% to 54% [2][3] - Honghe Technology anticipates a net profit of 193 million to 226 million yuan in 2025, showing a remarkable year-on-year growth of 745% to 889% [5] - Baiwei Storage expects a net profit of 850 million to 1 billion yuan in 2025, reflecting a year-on-year increase of 427.19% to 520.22% [7] Group 2: Fund Holdings and Activity - As of the end of 2025, 78 fund companies hold products that include Zijin Mining, with notable funds managed by well-known managers [2] - 96 fund companies have products holding Industrial Fulian, with E Fund being the largest holder [3] - 40 fund companies have products holding Baiwei Storage, with several funds increasing their holdings in the fourth quarter of 2025 [7] - Multiple fund companies have newly entered the institutional investor list for Honghe Technology and Tonghua Dongbao in the fourth quarter of 2025 [6][11] Group 3: Market Trends and Predictions - 604 listed companies are expected to have a lower limit of net profit growth of 100% or more in 2025, indicating a strong performance outlook [4] - Fund companies are focusing on companies with significant earnings growth and those expected to turn losses into profits, such as *ST Songfa and Tonghua Dongbao [9][10]

Core Viewpoint - The acquisition of Gao Xin Retail by Dehong Capital marks a significant investment, with a total amount exceeding 13 billion HKD, and has led to comprehensive reforms within the company, including key personnel changes and a shift in operational strategy [1][8]. Group 1: Acquisition Details - Dehong Capital completed the acquisition of Gao Xin Retail, the parent company of the supermarket chain RT-Mart, in February 2025, representing the largest investment since the firm's establishment [1]. - The acquisition involved purchasing 78.7% of Gao Xin Retail's shares from Alibaba for approximately 13.14 billion HKD, with a per-share cost of about 1.75 HKD [8]. Group 2: Management Changes - Following the acquisition, Dehong Capital appointed its co-founder and CEO, Hua Yuning, as the chairman of Gao Xin Retail, while the newly appointed CEO, Li Weiping, became the sole executive director responsible for daily operations [1][4]. - Li Weiping went missing just two months after taking office, leading to concerns about the company's leadership and operational continuity [2][4]. Group 3: Operational Strategy - Dehong Capital has initiated a shift in Gao Xin Retail's operational focus from "scale expansion" to "quality enhancement," with plans to invest resources in the renovation of 500 stores over the next three years [8][9]. - The company aims to transform its stores into community life centers, reducing store sizes to between 6,000 and 7,500 square meters and streamlining the product range to approximately 15,000 SKUs [9]. Group 4: Market Response - Despite the leadership crisis following Li Weiping's disappearance, Gao Xin Retail's stock price saw an increase, indicating market confidence or speculation regarding the company's future [5].

Core Viewpoint - Tonghua Dongbao Pharmaceutical Co., Ltd. has received an administrative regulatory measure from the Jilin Securities Regulatory Bureau, addressing issues related to the mixed use of properties with its controlling shareholder, lack of lease agreements, and rent payments, which the company is committed to rectify [1] Group 1: Regulatory Measures - The company acknowledges the regulatory measures and emphasizes its commitment to comply with relevant laws and regulations, aiming to enhance corporate governance [1] - The identified issues reflect weaknesses in the company's governance structure and independent management, prompting a comprehensive internal management system improvement [1] - The regulatory measures are characterized as routine oversight and are not expected to impact the company's normal production and operational activities [1] Group 2: Financial Performance and Growth - The company forecasts a net profit of approximately 1.242 billion yuan for 2025, indicating a turnaround from losses compared to the previous year [2] - The anticipated profit increase is primarily driven by the company's competitive advantage in insulin procurement, leading to rapid market share growth for insulin products [2] - The company has also seen significant growth in other products, such as liraglutide injection and empagliflozin tablets, contributing to a substantial rise in domestic sales revenue [2] Group 3: Strategic Focus - As a leading player in the domestic insulin market, the company plans to continue focusing on its core business, increasing R&D investment, and advancing international expansion [2] - The company aims to optimize its product structure and enhance core competitiveness while maintaining stable operational performance and improving corporate governance [2]

Core Viewpoint - The pharmaceutical sector is experiencing a mixed performance in 2025, with a significant number of companies forecasting profit increases, while others are facing substantial losses. Group 1: Profit Forecasts - A total of 283 pharmaceutical stocks have disclosed their 2025 earnings forecasts, with 160 companies expecting year-on-year profit growth. Among these, Sino Medical has the highest projected increase, with an expected profit growth of over 32 times [1][4]. - WuXi AppTec is anticipated to achieve a record net profit of 19.15 billion yuan, marking the highest since its listing. This includes nearly 5.6 billion yuan in non-recurring gains from the sale of equity interests [6]. - Sino Medical's projected net profit for 2025 is between 43 million and 50 million yuan, reflecting a year-on-year increase of 2,767% to 3,233%. The growth is attributed to stable revenue from its neuro-interventional business and a 22% increase in its coronary intervention business due to the implementation of a national procurement policy [4][5]. Group 2: Loss Forecasts - Over 120 companies are forecasting profit declines for 2025, with 39 facing their first losses since going public, including companies like Zhifei Biological and Zhenbao Island. Zhifei is expected to report a loss of between 10.698 billion and 13.726 billion yuan, a decline of 630% to 780% compared to the previous year [2][8]. - Zhenbao Island anticipates a net loss of between 1.012 billion and 1.173 billion yuan, attributed to delays in the procurement process and increased cost control measures [8]. - Huiyu Pharmaceutical's losses are primarily due to non-core investment losses, with a fair value loss of 173 million yuan from its investment in Zhejiang Tongyuan Kang Pharmaceutical [9]. Group 3: Innovative Drug Companies - The innovative drug sector is showing signs of recovery, with companies like Nocera and Rongchang Biopharma expected to turn losses into profits. Nocera forecasts a net profit of approximately 633 million yuan, a significant increase from the previous year [3][11]. - Rongchang Biopharma is also expected to achieve profitability with projected revenues of around 3.25 billion yuan, a year-on-year increase of about 89% [11]. - Companies like Junshi Biosciences are reducing their losses significantly, with an expected net loss of around 873 million yuan, a reduction of 408 million yuan compared to the previous year [11][12].

Market Overview - The biopharmaceutical sector increased by 1.27% on February 3, with Wanzhe Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Stock Performance - Wanzhe Co., Ltd. (000534) closed at 30.65, with a rise of 10.01% and a trading volume of 313,500 shares, amounting to a transaction value of 921 million yuan [1] - Other notable performers included ST Weiming (002581) with a 5.01% increase, closing at 7.55, and Nearshore Protein (688137) with a 4.84% increase, closing at 44.20 [1] Capital Flow - The biopharmaceutical sector experienced a net outflow of 255 million yuan from institutional investors and 153 million yuan from retail investors, while retail investors saw a net inflow of 408 million yuan [2] - The capital flow for individual stocks showed that Wanzhe Co., Ltd. had a net outflow of 50.83 million yuan from institutional investors, while retail investors contributed a net inflow of 15.59 million yuan [3] Individual Stock Analysis - Eurolin Biotech (688319) had a net inflow of 21.61 million yuan from institutional investors, while ST Weiming (002581) saw a significant net inflow of 13.51 million yuan [3] - Conversely, major outflows were noted in Wanzhe Co., Ltd. and other stocks, indicating varied investor sentiment across the sector [3]

重要内容提示： ■ 一、回购股份的基本情况 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"）于2025年10月17日召开第十一届董事会第 十八次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资 金以集中竞价交易方式回购公司股份，回购后的股份将用于员工持股计划及/或股权激励。在回购股份 价格不超过人民币10元/股（含），资金总额不低于人民币2,000万元（含），不超过人民币4,000万元 （含）。回购期限为自公司董事会审议通过回购股份方案之日起6个月内。内容详见公司于2025年10月 18日在中国证券报、上海证券报及上海证券交易所网站（www.sse.com.cn）披露的《通化东宝关于以集 中竞价交易方式回购公司股份方案的公告》《通化东宝关于以集中竞价交易方式回购股份的回购报告 书》。 二、回购股份的进展情况 2025年11月6日，公司按照股份回购方案实施了首次回购。内容详见公司于2025年11月7日在中国证券 报、上海证券报及上海证券交易所网站（www.sse.com.cn）披露的《通化东宝关于以集中竞价交易方式 首次回购公司股份的公告》（公告编号：2025-07 ...